Our findings showed that the modification of YSA peptide improved the cytotoxicity of YSA‐PEG‐TiOX/CTD to EphA2 overexpressing A549 non‐small cell lung cancer (NSCLC) than non‐YSA modified counterparts. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.